Latest News in the pharma Industry

Research & Development

Optibrium and Goldfinch Bio sign agreement for StarDrop license

Optibrium and Goldfinch Bio sign agreement for StarDrop license

9 May 2017

Goldfinch Bio’s researchers select StarDrop to guide successful drug discovery.

Read more 
New buprenorphine wafers could help thousands battling opioid addiction

New buprenorphine wafers could help thousands battling opioid addiction

8 May 2017

When compared with current hard sublingual tablets, the novel formulation dissolved quickly with no increased safety concerns and no demonstrable difference in efficacy.

Read more 
SGS Clinical Research announces results of FiH studies using novel virus as experimental challenge agent

SGS Clinical Research announces results of FiH studies using novel virus as experimental challenge agent

4 May 2017

Strain represents one of the common current circulating strains of influenza of a pandemic origin.

Read more 
NIH discovery in mice could lead to new class of medications to fight mid-life obesity

NIH discovery in mice could lead to new class of medications to fight mid-life obesity

3 May 2017

With lower rates of obesity, the researchers say rates of heart disease, diabetes, and other diseases that tend to increase with age, including cancer and Alzheimer’s disease, could fall as well.

Read more 
Isogenica introduces next-generation, fully synthetic human Fab antibody fragment library

Isogenica introduces next-generation, fully synthetic human Fab antibody fragment library

3 May 2017

Library claimed to offer "the most efficient route to therapeutic antibody lead identification".

Read more 
AstraZeneca’s Imfinzi receives FDA accelerated approval for previously treated patients with advanced bladder cancer

AstraZeneca’s Imfinzi receives FDA accelerated approval for previously treated patients with advanced bladder cancer

2 May 2017

Imfinzi is the cornerstone in an extensive immuno-oncology program across multiple cancer types and stages of disease.

Read more 
Concert Pharmaceuticals initiates CTP-543 Phase II trial in alopecia areata

Concert Pharmaceuticals initiates CTP-543 Phase II trial in alopecia areata

2 May 2017

Trial designed to evaluate the safety and efficacy of CTP-543 after 12 months of dosing with the primary efficacy analysis at week 24.

Read more 
Shire and Parion Sciences sign collaborative license agreement to advance P-321 for ophthalmic indications

Shire and Parion Sciences sign collaborative license agreement to advance P-321 for ophthalmic indications

1 May 2017

P-321 is a Phase II investigational topical treatment for dry eye disease.

Read more 
Takeda announces FDA Accelerated Approval of Alunbrig

Takeda announces FDA Accelerated Approval of Alunbrig

30 Apr 2017

Alunbrig approved for ALK+ metastatic non-small Cell lung cancer patients who have progressed on or are intolerant to crizotinib.

Read more 
Antidepressant may enhance drug delivery to the brain

Antidepressant may enhance drug delivery to the brain

27 Apr 2017

NIH rat study suggests amitriptyline temporarily inhibits the blood-brain barrier, allowing drugs to enter the brain.

Read more 
Regeneron and Sanofi receive FDA approval of a new once-monthly dosing option for Praluent Injection

Regeneron and Sanofi receive FDA approval of a new once-monthly dosing option for Praluent Injection

26 Apr 2017

Monthly dosing schedule now approved in both US and EU.

Read more 
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 program in migraine prevention

Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 program in migraine prevention

25 Apr 2017

Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the US; Novartis to gain exclusive rights in Canada,

Read more